clinical study of Panchabhautika oil Nasal Drop treatment in migraine.
Phase 1
- Conditions
- Health Condition 1: G439- Migraine, unspecified
- Registration Number
- CTRI/2020/01/022889
- Lead Sponsor
- PARUL INSTITUTE OF AYURVED
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
Patients with classical symptoms of Ardhavabhedaka and patient signs and symptoms with migraine.
Exclusion Criteria
Patients suffering from other systemic diseases.
Patients who are contraindicated for Nasya.
Patients of Ardhavabhedaka who are under other treatment modalities.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method relieving the symptoms of migraine.Timepoint: 8 weeks
- Secondary Outcome Measures
Name Time Method Improvement in patients daily routine work, improvement in migraine symptoms.Timepoint: 8 weeks
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie Panchabhautika taila's efficacy in Ardhavabhedaka (migraine) as per CTRI/2020/01/022889?
How does Panchabhautika taila nasal drops compare to triptans in migraine treatment efficacy in CTRI/2020/01/022889?
What biomarkers predict response to Panchabhautika taila nasya in migraine patients from CTRI/2020/01/022889?
What adverse events and safety profiles are reported in CTRI/2020/01/022889 Phase I trial of Panchabhautika taila nasal drops?
Are there combination therapies involving Panchabhautika taila and conventional migraine medications in CTRI/2020/01/022889?